Last-line multiple myeloma patients, who have exhauster other treatment options have been responding to oral drug inobrodib in combination with pomalidomide and dexamethasone (pom and dex).
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.
Dr. Matthias Jurytko takes over the CEO position of cellcentric
st, 2021
- As current site manager of the Mercedes-Benz plant in Wörth and former site manager of the Mercedes-Benz plant in Gaggenau, Dr. Matthias Jurytko has extensive expertise in the truck business and many years of management experience
KIRCHHEIM UNTER TECK, Germany, April 30, 2021 /PRNewswire/ Personnel changes at cellcentric, the 50:50 fuel cell joint venture between Daimler Truck AG and the Volvo Group: Dr. Matthias Jurytko will take over as Managing Director and CEO of cellcentric on June 1
st, 2021. In this role, he succeeds Dr. Andreas Gorbach, who will leave the company on April 30, 2021. Gorbach will continue to support the company in the future as a member of cellcentric s advisory board.